Journal of Bone Metabolism最新文献_第6页

Vitamin D Deficiency in Young Elite Soccer Players Residing Permanently in Regions above 55 Degrees North Latitude. 常住北纬55度以上地区青少年优秀足球运动员维生素D缺乏的研究

Journal of Bone Metabolism Pub Date : 2025-05-01 Epub Date: 2025-04-18 DOI: 10.11005/jbm.24.821

Eduard Bezuglov, Mikhail Vinogradov, Ilsiuiar Anishchenko, Timur Vakhidov, Elvira Usmanova, Georgiy Malyakin, Elizaveta Kapralova

{"title":"Vitamin D Deficiency in Young Elite Soccer Players Residing Permanently in Regions above 55 Degrees North Latitude.","authors":"Eduard Bezuglov, Mikhail Vinogradov, Ilsiuiar Anishchenko, Timur Vakhidov, Elvira Usmanova, Georgiy Malyakin, Elizaveta Kapralova","doi":"10.11005/jbm.24.821","DOIUrl":"10.11005/jbm.24.821","url":null,"abstract":"Background: Although the importance of maintaining optimal vitamin D levels is wellrecognized, vitamin D deficiency among athletes remains prevalent, particularly in regions located above 40 degrees north latitude. The study aimed to evaluate weekly cholecalciferol supplementation in correcting vitamin D deficiency in young soccer players.Methods: The study involved 49 young soccer players permanently residing above 55 degrees north latitude with 25-hydroxy-vitamin D (25[OH]D) deficiency, randomized into an experimental group (N=25; mean age, 13.0±2.78 years) and a control group (N=24; mean age, 12.3±3.14 years). Participants in the experimental group received 15,000 IU of cholecalciferol once a week for six weeks. Blood samples were collected twice in February and May: before and after the intervention. Serum levels of 25(OH)D, calcium, ionized calcium, phosphorus, and parathyroid hormone using mass spectrometry have been measured.Results: Baseline serum 25(OH)D levels were similar in both groups (15.59±2.66 ng/mL vs. 15.56±2.30 ng/mL; P>0.05). Post-intervention, levels rose to 30.25±5.17 ng/mL in the experimental group and 20.59±5.56 ng/mL in the control group, with significantly greater improvement in the experimental group (P<0.001). By the end, 60% of the experimental group reached normal 25(OH)D levels, compared to just 4.17% (N=1) in the control group. Other hematological parameters showed no significant intergroup differences (P>0.05).Conclusions: A six-week course of 15,000 IU weekly cholecalciferol effectively and safely corrects 25(OH)D deficiency in young soccer players residing permanently in regions above 55 degrees north latitude, with minimal impact from spring outdoor training.","PeriodicalId":15070,"journal":{"name":"Journal of Bone Metabolism","volume":"32 2","pages":"114-122"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12183357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144333214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Alveolar Bone Mesenchymal Stem Cells Exhibit Osteogenic Potential with Fewer Macrophages. 肺泡骨间充质干细胞具有成骨潜能，巨噬细胞较少。

Journal of Bone Metabolism Pub Date : 2025-05-01 Epub Date: 2025-05-31 DOI: 10.11005/jbm.25.847

Zhao Wang, Jaemin Joun, Ju Han Song, Jeong-Tae Koh

{"title":"Alveolar Bone Mesenchymal Stem Cells Exhibit Osteogenic Potential with Fewer Macrophages.","authors":"Zhao Wang, Jaemin Joun, Ju Han Song, Jeong-Tae Koh","doi":"10.11005/jbm.25.847","DOIUrl":"10.11005/jbm.25.847","url":null,"abstract":"Background: Mesenchymal stem cells (MSCs) derived from various tissues demonstrate regenerative potential in bone tissue engineering. However, bone marrow-derived MSCs (BMSCs) often contain macrophage contamination, necessitating additional purification steps such as liposomal clodronate treatment. In contrast, alveolar bone MSCs alveolar bone-derived MSCs (aBMSCs) may offer a distinct advantage due to their lower macrophage contamination.Methods: The aBMSCs were isolated from alveolar bone fragments through enzymatic digestion, and their macrophage contamination was compared to BMSCs using flow cytometry for MSC surface markers (CD44, CD105, CD90.2, CD140a) and macrophage markers (CD11b).Results: The aBMSCs exhibited significantly lower macrophage contamination compared to BMSCs and maintained osteogenic potential. Under inflammatory conditions in the presence of interleukin-1β (IL-1β), aBMSCs maintained their osteogenic capacity-unlike BMSCs, whose differentiation was impaired-accompanied by further activation of Protocadherin FAT4 (FAT4), which is known to initiate the osteogenic differentiation trajectory of aBMSCs.Conclusions: These results highlight aBMSCs as a promising cell source for bone regeneration, offering low macrophage contamination and sustained osteogenic potential under inflammatory conditions such as IL-1β exposure.","PeriodicalId":15070,"journal":{"name":"Journal of Bone Metabolism","volume":"32 2","pages":"83-92"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12183363/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144333201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of Differences in Cell Migration during the Osteogenic and Adipogenic Differentiation of the Bone Marrow-Derived Stem Cells. 骨髓干细胞成骨和成脂分化过程中细胞迁移差异的比较。

Journal of Bone Metabolism Pub Date : 2025-05-01 Epub Date: 2025-05-31 DOI: 10.11005/jbm.25.841

Anirban Sardar, Shikha Verma, Anuj Raj, Bhaskar Maji, Ritu Trivedi

{"title":"Comparison of Differences in Cell Migration during the Osteogenic and Adipogenic Differentiation of the Bone Marrow-Derived Stem Cells.","authors":"Anirban Sardar, Shikha Verma, Anuj Raj, Bhaskar Maji, Ritu Trivedi","doi":"10.11005/jbm.25.841","DOIUrl":"10.11005/jbm.25.841","url":null,"abstract":"Background: The bone marrow niche comprises diverse cellular populations, including multipotent bone marrow-derived stem cells (BMSCs). Understanding the biology underlying the differentiation of BMSCs into osteogenic and adipogenic commitment in preserving bone health is key due to their inverse correlation. Biological processes such as cellular migration also serve as a crucial player during this differentiation and eventually contribute to various skeletal pathologies such as fractures, osteoporosis, and osteoarthritis. This is also crucial in developing various regenerative therapies involving BMSCs.Methods: To explore the differential migration of BMSCs, cells were initially directed into osteogenic or adipogenic commitment as confirmed by the mineralized matrix and lipid droplet formation for osteogenic and adipogenic commitment, respectively. The differential level of cellular migration was then assessed using the scratch wound healing assay, cell adhesion assay, and transwell migration assay.Results: The cellular differentiation was confirmed by the differential expression patterns of key markers, as determined by quantitative real-time reverse transcription-polymerase chain reaction and immunoblotting study. Moreover, the migration data indicates that BMSCs undergoing osteogenic commitment tend to migrate more compared to adipogenic cells, which is possibly attributed to the differential expression of integrins such as Itgα1, and Itgα5. The putative role of the Sdf1/Cxcr4 axis in this account was further established by utilizing a selective inhibitor of Cxcr4.Conclusions: This study sheds light on the differential migratory property of the BMSCs directed towards a specific lineage. It also highlights the need for a comprehensive understanding of the intricate biological interplay governing this peculiar cellular behaviour.","PeriodicalId":15070,"journal":{"name":"Journal of Bone Metabolism","volume":"32 2","pages":"69-82"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12183369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144333202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Calcium Supplementation: To Do or Not to Do. 补钙：做还是不做。

Journal of Bone Metabolism Pub Date : 2025-02-01 Epub Date: 2025-02-28 DOI: 10.11005/jbm.24.775

Emanuella Graciela Borges Fonseca, Carlos Marques Dos Santos, Felipe Freire da Silva, Ana Tereza Amoedo Martinez, Jozélio Freire de Carvalho

引用次数: 0

Treatment Goals for Prevention of Vertebral Fractures in Patients with Rheumatoid Arthritis. 类风湿关节炎患者椎体骨折预防的治疗目标。

Journal of Bone Metabolism Pub Date : 2025-02-01 Epub Date: 2025-02-28 DOI: 10.11005/jbm.24.811

Takeshi Mochizuki, Mari Ando, Koichiro Yano, Ryo Hiroshima, Katsunori Ikari, Ken Okazaki

{"title":"Treatment Goals for Prevention of Vertebral Fractures in Patients with Rheumatoid Arthritis.","authors":"Takeshi Mochizuki, Mari Ando, Koichiro Yano, Ryo Hiroshima, Katsunori Ikari, Ken Okazaki","doi":"10.11005/jbm.24.811","DOIUrl":"10.11005/jbm.24.811","url":null,"abstract":"Background: Patients with rheumatoid arthritis (RA) are at an increased risk of osteoporosis and vertebral fractures. This study aimed to investigate factors associated with vertebral fractures and treatment goals to prevent new vertebral fractures in patients with RA.Methods: The database used in this study included outpatient data of RA patients at the authors' hospital of RA patients taken from 2018 to 2022. The patients underwent annual imaging evaluations to assess parameters, including bone mineral density of the lumbar spine (LS; L2-4), total hip, and femoral neck, as well as vertebral fractures. Vertebral fractures were evaluated using radiographic images of the T8 to L5 vertebrae.Results: The prevalence rates of new vertebral fractures in 2018-2019, 2019-2020, 2020- 2021, and 2021-2022 were 2.0%, 1.3%, 2.3%, and 2.0%, respectively. The presence of existing vertebral fractures was associated with new vertebral fractures (p=0.003; odds ratio, 0.241; 95% confidence interval, 0.093-0.624). The cut-off T-score values for the LS for new vertebral fractures in patients with or without pre-existing vertebral fractures were -0.7 (sensitivity, 40.9%; specificity, 100%) and -1.4 (sensitivity, 69.0%; specificity, 62.5%), respectively.Conclusions: The presence of pre-existing vertebral fractures is an independent factor associated with new vertebral fractures. It is important to tailor treatment goals based on the presence or absence of vertebral fractures to effectively prevent new fractures.","PeriodicalId":15070,"journal":{"name":"Journal of Bone Metabolism","volume":"32 1","pages":"49-56"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11960298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacogenetics of Response to Bisphosphonate Treatment in Postmenopausal Osteoporosis: A Prospective Study. 绝经后骨质疏松患者对双膦酸盐治疗反应的药物遗传学：一项前瞻性研究。

Journal of Bone Metabolism Pub Date : 2025-02-01 Epub Date: 2025-02-28 DOI: 10.11005/jbm.24.787

Sirin Akbulut Ayturk, Ozden Ozyemisci Taskiran, Ebru Koseoglu Tohma, Aylin Sepici Dincel, Nesrin Demirsoy, Vesile Sepici

{"title":"Pharmacogenetics of Response to Bisphosphonate Treatment in Postmenopausal Osteoporosis: A Prospective Study.","authors":"Sirin Akbulut Ayturk, Ozden Ozyemisci Taskiran, Ebru Koseoglu Tohma, Aylin Sepici Dincel, Nesrin Demirsoy, Vesile Sepici","doi":"10.11005/jbm.24.787","DOIUrl":"10.11005/jbm.24.787","url":null,"abstract":"Background: This study aims to investigate the effect of genetic polymorphisms of vitamin D receptor (VDR), estrogen receptor 1 (ER1), and Col1a1 on the response to bisphosphonate (BP) therapy in women with postmenopausal osteoporosis (OP).Methods: Twenty-one women with postmenopausal OP who received alendronate, ibandronate, or zoledronic acid for one year were enrolled in this study. Bone mineral density (BMD) at the lumbar spine and femoral neck were assessed by dual energy X-ray absorptiometry at baseline and after 12 months. Serum osteocalcin levels were measured at baseline and after 12 months. Polymorphic sites of the genes encoding ER1, VDR and Col1a1 proteins were amplified by polymerase chain reaction and examined using restriction fragment length polymorphism. Response to BP treatment and change in osteocalcin levels were compared among women with different gene polymorphisms.Results: Ratio of responders to treatment regarding improvements in the BMD of lumbar spine and femoral neck was adequate in 76% and 62%, respectively. There was no significant difference in treatment response regarding BMD in either region or change in serum osteocalcin levels among different gene polymorphisms.Conclusions: These findings did not support the potential role of VDR BsmI, Col1a1 Sp1, ER1 PvuII, or XbaI polymorphisms in predicting the response to BP therapy in women with postmenopausal OP. Further investigation with larger prospective studies is required.","PeriodicalId":15070,"journal":{"name":"Journal of Bone Metabolism","volume":"32 1","pages":"21-30"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11960302/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143647853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transforming Growth Factor-β Signaling Inhibits the Osteogenic Differentiation of Mesenchymal Stem Cells via Activation of Wnt/β-Catenin Pathway. 转化生长因子-β 信号通过激活 Wnt/β-Catenin 通路抑制间充质干细胞的成骨分化

Journal of Bone Metabolism Pub Date : 2025-02-01 Epub Date: 2025-02-28 DOI: 10.11005/jbm.24.761

Mahsa Tahoori, Azita Parvaneh Tafreshi, Fatemeh Naghshnejad, Bahman Zeynali

{"title":"Transforming Growth Factor-β Signaling Inhibits the Osteogenic Differentiation of Mesenchymal Stem Cells via Activation of Wnt/β-Catenin Pathway.","authors":"Mahsa Tahoori, Azita Parvaneh Tafreshi, Fatemeh Naghshnejad, Bahman Zeynali","doi":"10.11005/jbm.24.761","DOIUrl":"10.11005/jbm.24.761","url":null,"abstract":"Background: Due to the contradictory and temporally variable effects of transforming growth factor-β (TGF-β) and the Wnt/β-catenin pathways on osteogenic differentiation in different stem cell types, we sought to examine the activity of these pathways as well as their interaction during the osteogenic differentiation of the osteo-induced adiposederived mesenchymal stem cells (AD-MSCs).Methods: The osteo-induced AD-MSCs were treated with TGF-β1 (1 ng/mL) either alone or together with its antagonist SB- 431542 (10 μM) or that of the Wnt antagonist, inhibitor of Wnt production 2 (IWP2) (3 μM), every 3 days for 21 days. Cells were then analyzed for calcium deposit, bone matrix production, and the osteogenic markers gene expression.Results: Our results showed firstly that, either of the pathways is active since the mRNA expressions of their respective target genes, PAI-1 and Cyclin D1 were detectable although the latter was at a very low level. Secondly that, treatment with TGF-β1 decreased levels of calcium deposit, bone matrix production and the osteogenic markers gene expression. Accordingly, osteogenesis was induced in those treated with SB either alone or together with the TGF-β1, pointing to inhibitory effect of TGF-β pathway on osteogenic differentiation. Thirdly that following treatment with IWP2 and TGF-β1, the inhibitory effect of TGF-β1 on bone matrix production was reversed. Fourthly, there was constantly low expression of Wnt3amRNA but progressively increasing that of its endogenous antagonist Dkk-1mRNA throughout.Conclusions: Together these results suggest that TGF-β1 requires the active Wnt/β-catenin signaling pathway to exert its inhibitory effects on osteogenic differentiation of AD-MSCs.","PeriodicalId":15070,"journal":{"name":"Journal of Bone Metabolism","volume":"32 1","pages":"11-20"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11960301/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of Bisphosphonate in Patients with Neurofibromatosis Type 1. 双膦酸盐治疗1型神经纤维瘤病的疗效。

Journal of Bone Metabolism Pub Date : 2025-02-01 Epub Date: 2025-02-28 DOI: 10.11005/jbm.24.809

Arzu Jalilova, Alessandra Cocca

{"title":"Efficacy of Bisphosphonate in Patients with Neurofibromatosis Type 1.","authors":"Arzu Jalilova, Alessandra Cocca","doi":"10.11005/jbm.24.809","DOIUrl":"10.11005/jbm.24.809","url":null,"abstract":"This review aims to synthesize current knowledge regarding the use of bisphosphonates (BPs) in the treatment of bone complications in patients with neurofibromatosis type 1 (NF1). NF1 is a genetic disorder marked by multiple benign tumors of the nervous system and various skeletal abnormalities, such as osteoporosis and an increased risk of fractures. BPs are drugs that inhibit bone resorption, commonly used to treat osteoporosis and other bone diseases. The review identified multiple studies examining the effects of BP therapy in NF1 patients. Most studies reported improvements in bone mineral density and reduced fracture occurrence. The most commonly reported side effects were mild gastrointestinal symptoms and transient musculoskeletal pain. However, the evidence is limited by the small number of studies and the heterogeneity of patient populations and treatment protocols. In conclusion, BPs show improvements in managing NF1 complications such as osteoporosis and a reduction of fracture risk in NF1 patients. While the existing studies suggest positive outcomes, there is a need for more rigorous, large-scale studies to establish standardized treatment protocols and long-term safety profiles. Healthcare providers should consider BP therapy as a potential option for NF1 patients with significant bone complications, while also monitoring for possible adverse effects.","PeriodicalId":15070,"journal":{"name":"Journal of Bone Metabolism","volume":"32 1","pages":"1-10"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11960297/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Twenty-Year Trends in Osteoporosis Treatment and Post-Fracture Care in South Korea: A Nationwide Study. 韩国骨质疏松症治疗和骨折后护理的20年趋势：一项全国性研究。

Journal of Bone Metabolism Pub Date : 2025-02-01 Epub Date: 2025-02-28 DOI: 10.11005/jbm.24.829

Kyoung Jin Kim, Kyoung Min Kim, Young-Kyun Lee, Jihye Kim, Hoyeon Jang, Jaiyong Kim, Ha Young Kim

{"title":"Twenty-Year Trends in Osteoporosis Treatment and Post-Fracture Care in South Korea: A Nationwide Study.","authors":"Kyoung Jin Kim, Kyoung Min Kim, Young-Kyun Lee, Jihye Kim, Hoyeon Jang, Jaiyong Kim, Ha Young Kim","doi":"10.11005/jbm.24.829","DOIUrl":"10.11005/jbm.24.829","url":null,"abstract":"Background: Osteoporosis is a significant public health issue in aging populations. Despite advances in pharmacotherapy, underdiagnosis and undertreatment remain prevalent even in patients with recent fractures. This study examined 20-year trends (2002- 2022) in anti-osteoporotic medication (AOM) usage in South Korea.Methods: Data from the Korean National Health Information Database were retrospectively analyzed. The study included individuals aged ≥50 years and analyzed prescription trends, medication adherence, measured by the medication possession ratio (MPR), and treatment initiation rates post-fracture. The AOMs examined included bisphosphonates, selective estrogen receptor modulators, denosumab (DMAB), teriparatide (TPTD), and romosozumab (ROMO).Results: Over two decades, AOM use has shifted significantly from oral to injectable formulations, with injectables surpassing oral medications in 2020; from 397,440 prescriptions in 2016 to 1,162,779 in 2022. Prescriptions for DMAB surged following its approval as a first-line therapy in 2019, increasing 2.65 times from 217,606 in 2019 to 575,595 in 2022. The MPR improved from 35.4% in 2003 to 73.2% in 2021, with females demonstrating higher adherence than males. Post-fracture treatment rates increased from 31.1% in 2006 to 39.9% in 2021 but remained below 50%. Vertebral fractures had the highest treatment initiation rates, while anabolic agents, such as TPTD and ROMO were underprescribed despite their efficacy.Conclusions: This 20-year analysis highlights significant progress in osteoporosis management in South Korea, including a shift towards injectable therapies and improved adherence. However, the persistent undertreatment of high-risk patients underscores the requirement for enhanced access to anabolic agents, clinician education, and policy reforms to optimize post-fracture care.","PeriodicalId":15070,"journal":{"name":"Journal of Bone Metabolism","volume":"32 1","pages":"57-66"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11960296/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incidence of Hypercalcemia and Vertebral Fractures Following Denosumab Withdrawal in Lung Cancer Patients: A Longitudinal Cohort Study. 肺癌患者停用地诺单抗后高钙血症和椎体骨折的发生率：一项纵向队列研究。

Journal of Bone Metabolism Pub Date : 2025-02-01 Epub Date: 2025-02-28 DOI: 10.11005/jbm.24.803

Marta Villanova, Sharon H Chou, Le Min

{"title":"Incidence of Hypercalcemia and Vertebral Fractures Following Denosumab Withdrawal in Lung Cancer Patients: A Longitudinal Cohort Study.","authors":"Marta Villanova, Sharon H Chou, Le Min","doi":"10.11005/jbm.24.803","DOIUrl":"10.11005/jbm.24.803","url":null,"abstract":"Background: Bone-target agents (BTAs), including denosumab (DMAb), are one of the bone metastasis treatments that should continue indefinitely. However, BTAs may be interrupted in some cases. In osteoporosis, DMAb withdrawal causes a rebound effect characterized by an increased bone turnover with spine fractures and hypercalcemia; evidence of the DMAb withdrawal effect in oncology is lacking.Methods: This study aimed to identify the DMAb withdrawal effect amongst lung cancer patients treated with DMAb for bone metastases between January 2020 and December 2021. Patients who discontinued DMAb were included. Encounter notes, radiological and laboratory findings were comprehensively reviewed.Results: Thirty patients were included with a median follow-up of 21 months (interquartile range [IQR], 10-30) after DMAb discontinuation. Bisphosphonates were administered before starting DMAb in 7 patients (23.3%) and after DMAb withdrawal in 4 cases (13.3%). Three cases of DMAb withdrawal-related hypercalcemia and 3 cases of spine fractures following DMAb cessation were identified in 5 patients (16.7%), all of them were females and the median age was 65 years old (IQR, 65-70). No statistical difference in DMAb duration or number of injections was found in patients developing DMAb withdrawal-related spine fractures or hypercalcemia compared with others (binary logistic regression, p=0.688 and p=0.938, respectively).Conclusions: Patients with bony-metastatic lung cancer, especially post-menopausal women, are at risk of fractures and calcium abnormalities after DMAb discontinuation, suggesting that DMAb withdrawal effect may also be present in the oncological setting. A close follow-up and careful monitoring during and after discontinuation of DMAb is necessary.","PeriodicalId":15070,"journal":{"name":"Journal of Bone Metabolism","volume":"32 1","pages":"38-48"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11960300/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143647428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0